TSMC earnings; Oracle analyst meeting; Gold’s new high - what’s moving markets
Investing.com - Stifel raised its price target on Ionis Pharmaceuticals (NASDAQ:IONS) to $43.00 from $38.00 while maintaining a Hold rating following the FDA approval of Dawnzera. The new target aligns closely with the stock’s current trading price of $42.92, though analyst targets range widely from $38 to $83.
Ionis announced Thursday that Dawnzera (donidalorsen) received FDA approval for prophylaxis of hereditary angioedema (HAE) in patients 12 years and older. The drug’s label came in clean without major surprises, according to Stifel. The approval comes as Ionis, currently valued at $6.8 billion, has seen its shares surge 32% over the past six months.
The FDA recommended the 80mg Q4W (every four weeks) dose with the option to consider Q8W (every eight weeks) dosing. The Q4W dosing showed an improved mean reduction in phase 3 trials (81% versus 55%).
Stifel notes the key question going forward is how well Ionis can launch Dawnzera in the competitive HAE market. Management believes HAE patients continue to switch prophylactic treatments due to unmet needs with existing options.
Ionis management estimates Dawnzera can achieve peak sales exceeding $500 million, citing the drug’s efficacy, tolerability, and convenience as compelling factors that could drive patient switching. For deeper insights into Ionis’s financial health and growth potential, including 8 additional ProTips and comprehensive valuation metrics, visit InvestingPro.
In other recent news, Ionis Pharmaceuticals reported its second-quarter 2025 earnings, revealing a strong financial performance that exceeded revenue expectations. The company posted a revenue of $452 million, significantly surpassing the forecast of $286 million, marking a 58.04% revenue surprise. The earnings per share were $0.70, a substantial improvement from the anticipated -$0.24. Following these results, Morgan Stanley (NYSE:MS) upgraded Ionis Pharmaceuticals from Equalweight to Overweight, raising its price target to $62.00 from $55.00. H.C. Wainwright also raised its price target on the company to $65.00 from $50.00, maintaining a Buy rating, citing the strong launch of a treatment for familial chylomicronemia syndrome. Jefferies reiterated its Buy rating and $83.00 price target, maintaining a positive outlook. Meanwhile, BMO Capital maintained its Market Perform rating and a $40.00 price target, following FDA approval for Dawnzera. These developments highlight the company’s recent progress and analyst interest.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.